Combined Use of Low-dose Sugammadex Plus Neostigmine Administered for Reversal of Rocuronium

• Status: Unknown status
• Trial end date: 2018-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Reversal of rocuronium-induced neuromuscular block by the combination of low-doses of neostigmine plus sugammadex decreases the cost of anesthetic medications, while maintaining efficacy of reversal in obese patients.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Iuliu Hatieganu University of Medicine and Pharmacy
• Treatments: Atropine; Neostigmine; Rocuronium

Criteria

Inclusion Criteria:

• Patients scheduled for elective abdominal surgery

• 16-65 years of age

• BMI 30-39.9 ( obese class I-II)

• American Society of Anesthesiologists (ASA) physical status II.

• Surgery scheduled for general anesthesia and tracheal intubation and planned extubation at the end of surgery

• Surgical procedures with an anticipated length of at least 60 min.

Exclusion Criteria:

• Emergency surgery

• Patients unable to consent to study participation

• Patients expected to be maintained on mechanical ventilation postoperatively

• Contraindication to any of the study drugs

• Patients with existing neuromuscular disease

• Acute or chronic renal failure (GFR-EPI <30 mL/min/1.73 m2)

• Acute/chronic liver disease (Child-Pugh Score >1)

• Hyperkalemia (> 5.3 mmol/l)

• Pregnancy

• History of stroke or ongoing paresis

• Glaucoma

• Breast feeding

• Sepsis